Tater told CNBC-TV18, "Panacea Biotec is a turnaround story and if I see the entire development for the company, the company has bagged few orders; few large orders from UNICEF to a tune of over USD 300 million and we feel that there are only two key competitors to the business in the polio vaccine business in India. So we feel that the company would be getting consistent orders from UNICEF even going forward."
He further added, "If we see the entire financial position for the company, the company has recently completed a buyback on the stock and the company is going to post an EPS of over Rs 18-20. A pharma company available at a price of just 10 times forward is going to have one assured business from an organization like UNICEF."
"We feel the stock is under played and even if I compare this with the market leader Biocon we feel the stock that trades at 23-24 times forward that is Biocon and company like Panacea Biotech at 10 times, we feel the company would catch up the valuation to a tune of 14-15 times that means the stock in the longer term could mean Rs 250-300 levels but the target for the day would be Rs 197."
